市場調查報告書

癌症性腹膜炎(PC)- 流行病學預測 2028年

Peritoneal Carcinomatosis (PC) Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 918174
出版日期 內容資訊 英文 70 Pages
商品交期: 最快1-2個工作天內
價格
癌症性腹膜炎(PC)- 流行病學預測 2028年 Peritoneal Carcinomatosis (PC) Epidemiology Forecast to 2028
出版日期: 2019年12月01日內容資訊: 英文 70 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的癌症性腹膜炎(PC)的2017年的罹患數估算為9萬1,416人。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的癌症性腹膜炎(PC)市場相關調查,疾病概要,流行病學的預測,未滿足需求等資料彙整。

目錄

第1章 重要洞察

第2章 癌症性腹膜炎(PC)市場概要

  • 癌症性腹膜炎(PC)的分佈(實在數值)
  • 癌症性腹膜炎(PC)的分佈(預測值)

第3章 疾病背景和概要:癌症性腹膜炎(PC)

  • 簡介
  • 疾病的自然死亡
  • 病因的分類
  • 症狀
  • 病理生理學
  • 評分系統
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的癌症性腹膜炎(PC)的總患病數
  • 關鍵意見領袖的意見

第5章 假設和理論性根據

第6章 各國流行病學預測

  • 美國
    • 假設和理論性根據
    • 進行性癌症的癌症性腹膜炎(PC)的總罹患數
    • 侷限性癌症的癌症性腹膜炎(PC)的罹患數
    • 復發性癌症的癌症性腹膜炎(PC)的總罹患數
    • 侷限性復發癌症的癌症性腹膜炎(PC)的罹患數
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第7章 治療

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0397

DelveInsight's 'Peritoneal Carcinomatosis (PC)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Peritoneal Carcinomatosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Peritoneal Carcinomatosis Disease Understanding

Peritoneal Carcinomatosis (PC) generally refers to the metastatic involvement of peritoneum. It is a rare type of cancer that can develop when gastrointestinal or gynecologic cancers spread. It can cause tumors to grow in the peritoneum. Classically, it has been a condition of fatal evolution that leads to the death of the patient by cancer evolution in a period rarely exceeding 6 months. It is intraperitoneal dissemination of any form of cancer that does not originate from the peritoneum itself.

Peritoneal Carcinomatosis Epidemiology

The Peritoneal Carcinomatosis (PC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Peritoneal Carcinomatosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Peritoneal Carcinomatosis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases) scenario of Peritoneal Carcinomatosis (PC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of incident cases of Peritoneal Carcinomatosis (PC) in 7 MM was found to be 91,416 in the year 2017.

Report Scope

  • The report covers detailed overview of Peritoneal Carcinomatosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Peritoneal Carcinomatosis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases in 7MM

Key strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Key assessments

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the clients by providing them with the most up to date Report. It usually takes 24 Hours.

Table of Contents

1. Key Insights

2. Peritoneal Carcinomatosis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2017
  • 2.2. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Natural History of Peritoneal Carcinomatosis
  • 3.3. Classification of Causes of Peritoneal disease
  • 3.4. Symptoms of Peritoneal Carcinomatosis
  • 3.5. Pathophysiology of Peritoneal Carcinomatosis
  • 3.6. Scoring System
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Patient Population of Peritoneal Carcinomatosis
  • 4.3. KOL Views

5. Epidemiology - Assumptions and Rationale

6. Country Wise-Epidemiology of PC

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Incidence of PC in Advanced Stage Cancers
    • 6.1.3. Incidence of PC in Site Specific Cancers
    • 6.1.4. Total Incidence of PC in Recurrent Cases
    • 6.1.5. Incidence of PC by site-specific Recurrent Cases
  • 6.2. EU5 Countries
    • 6.2.1. Assumptions and Rationale
  • 6.3. Germany
    • 6.3.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.3.2. Incidence of PC in Site Specific Cancers
    • 6.3.3. Total Incidence of PC in Recurrent Cases
    • 6.3.4. Incidence of PC by site-specific Recurrent Cases
  • 6.4. France
    • 6.4.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.4.2. Incidence of PC in Site Specific Cancers
    • 6.4.3. Total Incidence of PC in Recurrent Cases
    • 6.4.4. Incidence of PC by site-specific Recurrent Cases
  • 6.5. Italy
    • 6.5.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.5.2. Incidence of PC in Site Specific Cancers
    • 6.5.3. Total Incidence of PC in Recurrent Cases
    • 6.5.4. Incidence of PC by site-specific Recurrent Cases
  • 6.6. Spain
    • 6.6.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.6.2. Incidence of PC in Site Specific Cancers
    • 6.6.3. Total Incidence of PC in Recurrent Cases
    • 6.6.4. Incidence of PC by site-specific Recurrent Cases
  • 6.7. United Kingdom
    • 6.7.1. Total Incidence of PC in Advanced Stage Cancers
    • 6.7.2. Incidence of PC in Site Specific Cancers
    • 6.7.3. Total Incidence of PC in Recurrent Cases
    • 6.7.4. Incidence of PC by site-specific Recurrent Cases
  • 6.8. Japan
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Incidence of PC in Advanced Stage Cancers
    • 6.8.3. Incidence of PC in Site Specific Cancers
    • 6.8.4. Total Incidence of PC in Recurrent Cases
    • 6.8.5. Incidence of PC by site-specific Recurrent Cases

7. Treatment

8. Unmet Needs

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1: Key morphological features identified in metastatic carcinoma in ascites
  • Table 2: Comparison of imaging techniques
  • Table 3: Total Population of Peritoneal Carcinomatosis in the 7MM (2017-2028)
  • Table 4: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
  • Table 5: Incidence of PC in Site Specific Cancers in the US (2017-2028)
  • Table 6: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
  • Table 7: Incidence of PC by site-specific Recurrent Cases in the US (2017-2028)
  • Table 8: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
  • Table 9: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
  • Table 10: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
  • Table 11: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
  • Table 12: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
  • Table 13: Incidence of PC in Site Specific Cancers in France (2017-2028)
  • Table 14: Total Incidence of PC in Recurrent Cases in France (2017-2028)
  • Table 15: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
  • Table 16: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
  • Table 17: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
  • Table 18: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
  • Table 19: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
  • Table 20: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
  • Table 21: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
  • Table 22: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
  • Table 23: Incidence of PC by site-specific Recurrent Cases in Spain (2017-2028)
  • Table 24: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
  • Table 25: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
  • Table 26: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
  • Table 27: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
  • Table 28: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
  • Table 29: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
  • Table 30: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
  • Table 31: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)

List of Figures

  • Figure 1: Anatomy of a Peritoneum
  • Figure 2: Types of Carcinomatosis
  • Figure 3: Ascites
  • Figure 4: Classification based on Primary and Secondary Tumors:
  • Figure 5: Classification based on Neoplastic and Non-neoplastic Conditions:
  • Figure 6: Tumor Entrapment Hypothesis in Gastric Cancer:
  • Figure 7: Symptoms of PC
  • Figure 8: The Peritoneal Metastatic Cascade:
  • Figure 9: The Peritoneal Cancer Index (PCI):
  • Figure 10: Diagnostic decision tree for identifying primary cancer which has metastatized to peritoneum
  • Figure 11: Total Diagnosed Patient Population of Peritoneal Carcinomatosiss in the 7MM (2017-2028)
  • Figure 12: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
  • Figure 13: Incidence of PC in Site Specific Cancers in the US (2017-2028)
  • Figure 14: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
  • Figure 15: Incidence of PC by site-specific Recurrent Case sin the US (2017-2028)
  • Figure 16: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
  • Figure 17: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
  • Figure 18: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
  • Figure 19: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
  • Figure 20: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
  • Figure 21: Incidence of PC in Site Specific Cancers in France (2017-2028)
  • Figure 22: Total Incidence of PC in Recurrent Cases in France (2017-2028)
  • Figure 23: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
  • Figure 24: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
  • Figure 25: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
  • Figure 26: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
  • Figure 27: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
  • Figure 28: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
  • Figure 29: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
  • Figure 30: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
  • Figure 31: Incidence of PC by site-specific Recurrent Case sin Spain (2017-2028)
  • Figure 32: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
  • Figure 33: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
  • Figure 34: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
  • Figure 35: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
  • Figure 36: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
  • Figure 37: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
  • Figure 38: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
  • Figure 39: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)
  • Figure 40: HIPEC Treatment
  • Figure 41: Treatment algorithm
  • Figure 42: Unmet Needs